Syndax announces topline results from Maxpire Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis
SNDX•Syndax Pharmaceuticals said its Maxpire Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint. The company will not pursue further development of axatilimab for IPF; the drug was well tolerated with no new safety signals.
1. Trial results
Syndax Pharmaceuticals said its Maxpire Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint. The company will not pursue further development of axatilimab in IPF.
2. Safety and other trials
Axatilimab was well tolerated in Maxpire, with no new safety signals. The drug continues in multiple chronic graft-versus-host disease trials, with results expected later this year and early 2028.
